7th Oncolytic Virotherapy Summit 2022

2021 was a landmark year for clinical readouts within the oncolytic virotherapy field, and now OV developers are poised and ready at the cusp of something remarkable and this promising therapeutic is set to be a critical modality within cancer immunotherapy. With rapid advances in this compelling therapeutic, the Oncolytic Virotherapy Summit returns this December 2022 for its 7th edition.

As a leading industry forum, leading global biopharma will unite once again for three days dedicated to all things OV, as experts showcase clinical case studies and lead us through discussions to uncover the critical bottlenecks preventing widespread patient treatment with this promising therapeutic

URLs:
Website: https://go.evvnt.com/1259262-0?pid=176 
Tickets: https://go.evvnt.com/1259262-2?pid=176
Brochure: https://go.evvnt.com/1259262-3?pid=176

Prices:
Drug Developer Pricing (Conference + Pre-Conference Workshop Day): USD 4097.00,
Drug Developer Pricing (Conference Only): USD 2999.00,
Vendor Pricing (Conference + Pre-Conference Workshop Day): USD 4897.00,
Vendor Pricing (Conference Only): USD 3599.00,
Academic and Not for Profit Pricing (Conference + Pre-Conference Workshop Day): USD 3497.00,
Academic and Not for Profit Pricing (Conference Only): USD 2599.00

Speakers: Antonio Chiocca, Chairman, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Barbara Haertl, Associate Vice President, Manufacturing Operations, Calidi Biotherapeutics, Bart Spiesschart, Principal scientist In vivo Pharmacology, Boehringer Ingelhiem, Boris Minev, President, Medical and Scientific Affairs, Calidi Biotherapeutics, Di Yu, Head of Translational Research, Elicera Therapeutics, Enoch Yue, Associate Director, Business Development Oncology Search and Evaluation, Bristol Myers Squibb, Erik Digman Wiklund, Chief Executive Officer, Targovax, Francesca Barone, Chief Scientific Officer, Candel Therapeutics, James Burke Chief Medical Officer CG Oncology, Jeff Lange Executive, Vice President, Business Development, Virogin Biotech, Johanna Kaufmann, Executive Vice President, Oncology, Codagenix Inc., John Bell, Senior Scientist, Ottawa Hospital Research Institute, John Goldberg, Chief Medical Officer, Oncorus Inc., Kaja Jeyanthan, Analytical Development Scientist in Viral Development and Manufacturing Science, Turnstone Biologics, Karen Ann, Chekris Senior Director Search and Evaluation, Bristol Myers Squibb, Muna Abdullahi, Researcher, Beacon Targeted Therapies, Natalia Ulyanova, Director Oncology Business Development, Search and Evaluation, Astellas, Neil Sheppard, Director and Head T Cell Engineering Lab, University of Pennsylvania Center for Cellular Immunotherapies, Patrik Erlmann, Head of Research Beyond Borders, Boehringer Ingelhiem, Paul Peter Tak, President and Chief Executive Officer, Candel Therapeutics, Robert Coffin, President and Chief R&D Officer, Replimune, Sari Pesonen, Chief Scientific Officer, Valo Therapeutics, Sharon Yavrom, Executive Director, Clinical Science, IMUGENE, Sheryl Tran, Senior Director Quality and Compliance, Vyriad, Stephen Russell, Chief Executive Officer, Vyriad, Inc., Steve Thorne, Chief Scientific Officer, Kalivir Immunotheraputics

Time: 8:00 am to 4:00 pm